Ventripoint Diagnostics (TSX. V: VPT) (OTC: VPTDF) interview with Dr. George Adams, CEO, discussing the company's innovative AI-driven medical imaging technology addressing the cardio and cancer markets. The company has recently entered commercialization stage, and Dr. Admas provides an updates on the sales pipeline, and future growth potential.
. . .
This content is available to members only.
If you are an existing member, please LOGIN
Note a member? Sign up for a FREE account ($89 per month value), and get immediate access. Free offer expires March 15, 2019.
Register New Account
Institutional / team access subscriptions, contact Melissa Walters 212-871-2057 ext 2